TY - JOUR
T1 - Treatment options for patients with triple-negative breast cancer
AU - Santana-Davila, Rafael
AU - Perez, Edith A.
N1 - Funding Information:
Dr. Rafael Santana-Davila has no competing interest. Dr. Edith A. Perez has research funding from Genentech, Sanofi-Aventis, and Roche.
PY - 2010
Y1 - 2010
N2 - Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainly due to the lack of molecular targets, little progress has been made in the treatment of patients with triple-negative breast cancer. Recent improved understanding of the natural history, pathophysiology, and molecular features of triple-negative breast cancers have provided new insights into management and therapeutic strategies for women affected with this entity. Ongoing and planned translational clinical trials are likely to optimize and improve treatment of women with this disease.
AB - Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainly due to the lack of molecular targets, little progress has been made in the treatment of patients with triple-negative breast cancer. Recent improved understanding of the natural history, pathophysiology, and molecular features of triple-negative breast cancers have provided new insights into management and therapeutic strategies for women affected with this entity. Ongoing and planned translational clinical trials are likely to optimize and improve treatment of women with this disease.
UR - http://www.scopus.com/inward/record.url?scp=77958479034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958479034&partnerID=8YFLogxK
U2 - 10.1186/1756-8722-3-42
DO - 10.1186/1756-8722-3-42
M3 - Review article
C2 - 20979652
AN - SCOPUS:77958479034
SN - 1756-8722
VL - 3
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
M1 - 42
ER -